AUTHOR=Huang Chengliang , Li Meizhang , Liu Ben , Zhu Huanbo , Dai Qun , Fan Xianming , Mehta Kathan , Huang Chao , Neupane Prakash , Wang Fen , Sun Weijing , Umar Shahid , Zhong Cuncong , Zhang Jun 

TITLE=Relating Gut Microbiome and Its Modulating Factors to Immunotherapy in Solid Tumors: A Systematic Review

JOURNAL=Frontiers in Oncology

VOLUME=11

YEAR=2021

URL=https://www.frontiersin.org/journals/oncology/articles/10.3389/fonc.2021.642110

DOI=10.3389/fonc.2021.642110

ISSN=2234-943X

ABSTRACT=<p><bold>Background:</bold> Gut microbiome is proved to affect the activity of immunotherapy in certain tumors. However, little is known if there is universal impact on both the treatment response and adverse effects (AEs) of immune checkpoint inhibitors (ICIs) across multiple solid tumors, and whether such impact can be modulated by common gut microbiome modifiers, such as antibiotics and diet.</p><p><bold>Methods:</bold> A systematic search in PubMed followed by stringent manual review were performed to identify clinical cohort studies that evaluated the relevance of gut microbiome to ICIs (response and/or AEs, 12 studies), or association of antibiotics with ICIs (17 studies), or impact of diet on gut microbiome (16 studies). Only original studies published in English before April 1st, 2020 were used. Qualified studies identified in the reference were also included.</p><p><bold>Results:</bold> At the phylum level, patients who had enriched abundance in <italic>Firmicutes</italic> and <italic>Verrucomicrobia</italic> almost universally had better response from ICIs, whereas those who were enriched in <italic>Proteobacteria</italic> universally presented with unfavorable outcome. Mixed correlations were observed for <italic>Bacteroidetes</italic> in relating to treatment response. Regarding the AEs, <italic>Firmicutes</italic> correlated to higher incidence whereas <italic>Bacteroidetes</italic> were clearly associated with less occurrence. Interestingly, across various solid tumors, majority of the studies suggested a negative association of antibiotic use with clinical response from ICIs, especially within 1-2 month prior to the initiation of ICIs. Finally, we observed a significant correlation of plant-based diet in relating to the enrichment of “ICI-favoring” gut microbiome (<italic>P</italic> = 0.0476).</p><p><bold>Conclusions:</bold> Gut microbiome may serve as a novel modifiable biomarker for both the treatment response and AEs of ICIs across various solid tumors. Further study is needed to understand the underlying mechanism, minimize the negative impact of antibiotics on ICIs, and gain insight regarding the role of diet so that this important lifestyle factor can be harnessed to improve the therapeutic outcomes of cancer immunotherapy partly through its impact on gut microbiome.</p>